Regulation of E2Fs and senescence by PML nuclear bodies

Genes and Development

Volumn 25, Issue 1, 2011, Pages 41-50

  Vernier, Mathieu ^a   Bourdeau, Véronique ^a   Gaumont Leclerc, Marie France ^a   Moiseeva, Olga ^a   Bégin, Virginie ^a   Saad, Fred ^b   Mes Masson, Anne Marie ^b   Ferbeyre, Gerardo ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

E2F; PML; Prostate tumors; Retinoblastoma; Senescence

Indexed keywords

HETEROCHROMATIN PROTEIN 1; PHOSPHOPROTEIN PHOSPHATASE 1; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ARTICLE; CELL CYCLE; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENESCENCE; UPREGULATION;

CELL AGING; CELL LINE, TUMOR; CELL NUCLEUS; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; MALE; NUCLEAR PROTEINS; PROSTATIC HYPERPLASIA; PROTEIN TRANSPORT; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 78650906609     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1975111     Document Type: Article

References (60)

1. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, et al. 2008. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133: 1006-1018.
2. Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M, Szekely L, Helin K, Pelicci PG. 1998. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol 18: 1084-1093.
3. Armata HL, Garlick DS, Sluss HK. 2007. The ataxia telangiectasia- mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res 67: 11696-11703.
4. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, et al. 2006. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633-637.
5. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. 2002. Deconstructing PML-induced premature senescence. EMBO J 21: 3358-3369.
6. Bischof O, Nacerddine K, Dejean A. 2005. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol Cell Biol 25: 1013-1024.
7. Bourdeau V, Baudry D, Ferbeyre G. 2009. PML links aberrant cytokine signaling and oncogenic stress to cellular senescence. Front Biosci 14: 475-485.
8. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt CA. 2005. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665.
9. Calabrese V, Mallette FA, Deschenes-Simard X, Ramanathan S, Gagnon J, Moores A, Ilangumaran S, Ferbeyre G. 2009. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 36: 754-767.
10. Cao L, Li W, Kim S, Brodie SG, Deng CX. 2003. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 17: 201-213.
11. Chang IY, Jin M, Yoon SP, Youn CK, Yoon Y, Moon SP, Hyun JW, Jun JY, You HJ. 2008. Senescence-dependent MutSα dysfunction attenuates mismatch repair. Mol Cancer Res 6: 978-989.
12. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
13. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M, Lowe SW. 2010. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17: 376-387.
14. Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE, Benson MC. 2000. Expression of senescence-associated β-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 56: 160-166.
15. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML. 2006. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 66: 11897-11906.
16. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, Lowe SW. 2004. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13: 523-535.
17. Diallo JS, Aldejmah A, Mouhim AF, Peant B, Fahmy MA, Koumakpayi IH, Sircar K, Begin LR, Mes-Masson AM, Saad F. 2007. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13: 7044-7052.
18. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre M, Nuciforo PG, Bensimon A, et al. 2006. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444: 638-642.
19. Dimri GP, Hara E, Campisi J. 1994. Regulation of two E2Frelated genes in presenescent and senescent human fibroblasts. J Biol Chem 269: 16180-16186.
20. Dyson N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262.
21. Essaghir A, Toffalini F, Knoops L, Kallin A, van Helden J, Demoulin JB. 2010. Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res 38: e120. doi: 10.1093/nar/gkq149.
22. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015-2027.
23. Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, et al. 2010. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res 70: 3136-3139.
24. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185-6195.
25. Gotea V, Ovcharenko I. 2008. DiRE: Identifying distant regulatory elements of co-expressed genes. Nucleic Acids Res 36: W133-W139. doi: 10.1093/nar/gkn300.
26. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Paolo Pandolfi P. 2000. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736.
27. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96: 269-279.
28. Helt AM, Galloway DA. 2001. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol 75: 6737-6747.
29. Kakizuka A, Miller WHJ, Umesono K, Warrell RPJ, Frankel SR, Murty VV, Dmitrovsky E, Evans RM. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML. Cell 66: 663-674.
30. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. 2003. NF-kB nuclear localization and its prognostic significance in prostate cancer. BJU Int 91: 417-420.
31. Li W, Ferguson BJ, Khaled WT, Tevendale M, Stingl J, Poli V, Rich T, Salomoni P, Watson CJ. 2009. PML depletion disrupts normal mammary gland development and skews the composition of the mammary luminal cell progenitor pool. Proc Natl Acad Sci 106: 4725-4730.
32. Maehara K, Yamakoshi K, Ohtani N, Kubo Y, Takahashi A, Arase S, Jones N, Hara E. 2005. Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. J Cell Biol 168: 553-560.
33. Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O, Ferbeyre G. 2004. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23: 91-99.
34. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. 2007. The DNA damage signaling pathway is a critical mediator of oncogeneinduced senescence. Genes Dev 21: 43-48. (Pubitemid 46089705)
35. Michaloglou C, Vredeveld LC, SoengasMS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724.
36. Moiseeva O, Bourdeau V, Roux A, Deschenes-Simard X, Ferbeyre G. 2009. Mitochondrial dysfunction contributes to oncogeneinduced senescence. Mol Cell Biol 29: 4495-4507.
37. Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K. 2001. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15: 267-285.
38. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716.
39. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA, Myers MP, Lowe SW. 2006. A novel role for highmobility group a proteins in cellular senescence and heterochromatin formation. Cell 126: 503-514.
40. Neri S, Pawelec G, Facchini A, Mariani E. 2007. Microsatellite instability and compromised mismatch repair gene expression during in vitro passaging of monoclonal human T lymphocytes. Rejuvenation Res 10: 145-156.
41. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE, et al. 2001. Rb targets histone H3 methylation and HP1 to promoters. Nature 412: 561-565.
42. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J. 2002. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 133: 105-111.
43. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, Wappler I, Birket MJ, Harold G, Schaeuble K, et al. 2007. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 5: e110. doi: 10.1371/journal.pbio.0050110. (Pubitemid 46790403)
44. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, et al. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210.
45. Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM. 1992. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66: 2418-2427.
46. Regad T, Bellodi C, Nicotera P, Salomoni P. 2009. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci 12: 132-140.
47. Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R, Peeper DS. 2002. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2: 55-65.
48. Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. 2009. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 15: 1558-1565.
49. Seeler JS, Marchio A, Sitterlin D, Transy C, Dejean A. 1998. Interaction of SP100 with HP1 proteins: A link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci 95: 7316-7321.
50. Smith EJ, Leone G, DeGregori J, Jakoi L, Nevins JR. 1996. The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol Cell Biol 16: 6965-6976.
51. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
52. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT. 1999. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13: 152-157.
53. Vigo E, Muller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC, Helin K. 1999. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol 19: 6379-6395.
54. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551.
55. Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB, Maki CG. 2003. Physical and functional interactions between PML and MDM2. J Biol Chem 278: 29288-29297.
56. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S, Chang KS. 2001. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21: 2259-2268.
57. Xu X, Bieda M, Jin VX, Rabinovich A, Oberley MJ, Green R, Farnham PJ. 2007. A comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members. Genome Res 17: 1550-1561.
58. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, Adams PD. 2007. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 27: 2452-2465.
59. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, et al. 2005. Formation of MacroH2A-containing senescence- associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 8: 19-30.
60. Zhang X, Sejas DP, Qiu Y, Williams DA, Pang Q. 2007. Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. J Cell Sci 120: 1572-1583.